Patents Assigned to Karo Bio AB
-
Patent number: 8921402Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: GrantFiled: January 10, 2014Date of Patent: December 30, 2014Assignee: Karo Bio ABInventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
-
Publication number: 20140128435Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: KARO BIO ABInventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
-
Patent number: 8710243Abstract: The invention provides a compound of formula(I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. Formula(I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification.Type: GrantFiled: October 6, 2010Date of Patent: April 29, 2014Assignee: Karo Bio ABInventors: Lars Hagberg, Sandra Gordon, Aiping Cheng, Theresa Apelqvist, Patrik Rhönnstad, Mattias Wennerstål
-
Patent number: 8653112Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: GrantFiled: October 6, 2010Date of Patent: February 18, 2014Assignee: Karo Bio ABInventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
-
Patent number: 8653072Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R1, R2, R3, R5 and R6 are as defined in the specification.Type: GrantFiled: January 11, 2013Date of Patent: February 18, 2014Assignee: Karo Bio ABInventors: Patrik Rhonnstad, Elisabet Kallin, Theresa Apelqvist, Mattias Wennerstal, Aiping Cheng
-
Publication number: 20130131061Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R1, R2, R3, R5 and R6 are as defined in the specification.Type: ApplicationFiled: January 11, 2013Publication date: May 23, 2013Applicant: KARO BIO ABInventors: Patrik Rhonnstad, Elisabet Kallin, Theresa Apelqvist, Mattias Wennerstal, Aiping Cheng
-
Patent number: 8367665Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification.Type: GrantFiled: April 16, 2009Date of Patent: February 5, 2013Assignee: Karo Bio ABInventors: Patrik Rhönnstad, Elisabet Kallin, Theresa Apelqvist, Mattias Wennerstål, Aiping Cheng
-
Publication number: 20120202861Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification.Type: ApplicationFiled: October 6, 2010Publication date: August 9, 2012Applicant: KARO BIO ABInventors: Mattias Wennerstål, Patrik Rhönnstad, Aiping Cheng, Sandra Gordon, Theresa Apelqvist, Lars Hagberg
-
Publication number: 20120202853Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: ApplicationFiled: October 6, 2010Publication date: August 9, 2012Applicant: KARO BIO ABInventors: Joakim Löfstedt, Xiongyu Wu, Lars Krüger
-
Patent number: 8124129Abstract: There is provided a hemihydrate of (3?,5?,7?,12?)-7,12-dihydroxy-3-{2-[{4-[17?-hydroxy-3-oxo-17?-prop-1-ynylestra-4,9-dien-11?-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2?=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.Type: GrantFiled: July 12, 2006Date of Patent: February 28, 2012Assignee: Karo Bio ABInventors: Russell Drew Cink, Daozhong Zou, Marvin Robert Leanna, Pascal H. Toma, Michelle Andrée Long
-
Patent number: 7956214Abstract: Provided are processes for the synthesis of aniline derivatives, specifically certain aniline derivatives which have activity as thyroid receptor ligands.Type: GrantFiled: June 15, 2009Date of Patent: June 7, 2011Assignees: Karo Bio AB, Bristol-Myers Squibb CompanyInventors: Ramakrishnan Chidambaram, Joydeep Kant, Raymond E. Weaver, Jurong Yu, Arun Ghosh
-
Publication number: 20100004271Abstract: The invention provides Compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, wherein R3, R4, G, Y, W and R5 are as defined in the specification. The invention also provides the use of such Compounds in the treatment or Prophylaxis of a condition associated with a disease or disorder associated with thyroid receptor activity.Type: ApplicationFiled: July 4, 2006Publication date: January 7, 2010Applicant: KARO BIO ABInventors: Ana Maria Garcia Collazo, Eva Kristina Koch, Anton Joakim Lofstedt, Aiping Cheng, Thomas Fredrik Hansson, Edouard Zamaratski
-
Publication number: 20090233979Abstract: The invention provides compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, (I) wherein R1, R2, R3, R4, R5, R6, Y and W are as defined in the specification. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition that may be treated with a thyroid receptor agonist or partial agonist.Type: ApplicationFiled: May 24, 2007Publication date: September 17, 2009Applicant: KARO BIO ABInventors: Ana Maria Garcia Collazo, Eva Kristina Koch, Lars Johan Malm, Aiping Cheng, Tomas Fredrik Hansson
-
Patent number: 7521439Abstract: This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.Type: GrantFiled: July 21, 2006Date of Patent: April 21, 2009Assignee: Karo Bio ABInventors: Richard D. Bishop, Russell Drew Cink, Bradley D. Gates, Lars T. Hagberg, Peer B. Jacobsen, Philip R. Kym, Chunqiu Lai, Marvin Robert Leanna, James T. Link, Steven J. Richards, Noah Tu, Tom W. von Geldern
-
Publication number: 20080221210Abstract: The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I), wherein R1, R2, n, Y, Y?, R3, R4, W and R5 are as defined in the specification.Type: ApplicationFiled: March 22, 2005Publication date: September 11, 2008Applicant: Karo Bio ABInventors: Ana Maria Garcia Collazo, Thomas Anders Wilson Norin, Neerai Garg, Anton Joakim Lofstedt, Tomas Fredrik Hansson, Lars Jesper Hallberg, Peter Brandt
-
Patent number: 7342127Abstract: Novel thyroid receptor ligands are provided having the general formula I wherein X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.Type: GrantFiled: January 23, 2004Date of Patent: March 11, 2008Assignees: Bristol-Myers Squibb Company, Karo Bio ABInventors: William N. Washburn, Wei Meng, Denis E. Ryono, Bruce A. Ellsworth, Thomas Ericsson, Mahmoud Rahimi-Ghadim, Neeraj Garg, Johan Malm
-
Patent number: 7319163Abstract: This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac arrhythmias, thyrotoxicosis and subclinical hyperthyrodism.Type: GrantFiled: June 24, 2005Date of Patent: January 15, 2008Assignee: Karo Bio ABInventors: Johan Malm, Chris Litten, Theresa Apelqvist, Asa Hedfors, Peter Brandt, Karin Edvinsson, Sandra Gordon
-
Patent number: 7319096Abstract: This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyrodism and liver diseases.Type: GrantFiled: April 15, 2002Date of Patent: January 15, 2008Assignee: Karo Bio ABInventors: Johan Malm, Peter Brandt, Karin Edvinsson, Thomas Ericsson, Sandra Gordon
-
Publication number: 20080004251Abstract: The invention provides compounds of formula I or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I) wherein R1, R2, n, Y, Y?, R3, R4, W and R5 are as defined in the specification.Type: ApplicationFiled: March 22, 2005Publication date: January 3, 2008Applicant: KARO BIO ABInventors: Ana Garcia Collazo, Thomas Ericsson, Neeraj Garg, Anton Lofstedt, Tomas Hansson
-
Patent number: 7288571Abstract: New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR?R?) or an acylsulphonamide (CONHSO2R?) derivative, or a pharmaceutically acceptable salt thereof, and all stereolsom thereof; or when n is equal to or greater than one, R4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR?R?). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5—H).Type: GrantFiled: July 26, 2005Date of Patent: October 30, 2007Assignee: Karo Bio ABInventors: Jon Hangeland, Minsheng Zhang, Yolanda Caringal, Denis Ryono, Yi-Lin Li, Johan Malm, Ye Liu, Neeraj Garg, Chris Litten, Ana Maria Garcia Collazo, Konrad Koehler